The neuroscience market share in 2026 encompasses technologies, instruments, and consumables used to study the nervous system, investigate brain functions, and support the diagnosis and management of neurological conditions. These solutions are used across hospitals, diagnostic centers, academic institutions, and pharmaceutical research facilities. Growing research into neurodegenerative diseases, mental health conditions, and brain injuries is increasing the need for advanced neuroscience technologies. Neuro-imaging, neuro-microscopy, and electrophysiology systems are particularly important for examining brain structures, understanding neural activity, and supporting clinical and experimental research.
According to Fortune Business Insights, the global neuroscience market size was valued at USD 50.16 billion in 2025. The market is projected to grow from USD 53.01 billion in 2026 to USD 82.58 billion by 2034, exhibiting a CAGR of 5.7% during the forecast period. Rising prevalence of neurological disorders, increasing adoption of AI-enabled diagnostic technologies, and growing investments in personalized neurotherapies are driving growth in the neuroscience market. North America dominated the market with a revenue share of 38% in 2025.
Major companies operating in the global neuroscience market include:
Increasing Prevalence of Neurological Disorders Drives Demand
The rising prevalence of neurological and neurodegenerative disorders is a major factor supporting market growth. Conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy increase the need for advanced diagnostic and research technologies. Healthcare institutions are adopting neuro-imaging, electrophysiology, and neuro-microscopy systems to support early detection, clinical assessment, and neurological research.
Pharmaceutical companies also rely on neuroscience technologies during drug discovery, clinical trials, and the investigation of neurological conditions. Growing public awareness of brain health and mental wellness, along with government initiatives and research grants, further supports investment in this field. The integration of artificial intelligence and machine learning is improving the analysis of neurological data and strengthening the role of advanced technologies in research and clinical applications.
High Equipment Costs Restrict Wider Adoption
High costs associated with neuroscience instruments and specialized infrastructure remain important market restraints. Advanced imaging and electrophysiology systems require significant investment, which can limit adoption among smaller hospitals, clinics, and research centers. Maintenance expenses, specialized personnel requirements, and integration with existing clinical systems add to operational costs. Regulatory approval requirements, limited reimbursement policies, and the need for continuous professional training can also affect the adoption of new neuroscience technologies.
Emerging Opportunities in Personalized Neurotherapies